School of Medicine
  • Print
   
   

School staff listing

People listings by divisions

 

Image of Andrew Jackson

Andrew Jackson

Head Host-Tumour Interactions Group, Associate Professor, Chair Research Theme Committee, MSc Research Project and Host:Tumour Interface Module Convenor, Faculty of Medicine & Health Sciences

Contact

  • workAcademic Unit of Clinical Oncology
    Nottingham City Hospital
    Hucknall Road
    Nottingham
    NG5 1PB
    UK
  • work0115 82 31860
  • fax0115 82 31849

Teaching Summary

Lecturing advanced immunology to MSc Oncology and MSc Cancer Immunology & Biotechnology students.

Research Summary

The group lead by Dr Andrew Jackson and Professor Poulam Patel, comprises post-doctoral and clinical fellows, several PhD students, and a research technician and is supported by the MRC, industry… read more

Selected Publications

Current Research

The group lead by Dr Andrew Jackson and Professor Poulam Patel, comprises post-doctoral and clinical fellows, several PhD students, and a research technician and is supported by the MRC, industry (X-BioCell Ltd.), Breast Cancer Campaign, Matt's Fund for Cancer Research, and the University of Nottingham. Our research focuses on understanding the molecular pathways through which tumours suppress the immune system with a view to first-in-man immunotherapies.

Our recent focus has concerned targeting specific intracellular signaling pathways in dendritic cells (DC) to modify their function or restore immuno-suppression resulting from malignancy. Key areas of interest include ATM-kinase, p38-MAPK, MEK-ERK and the Unfolded Protein Response pathway (UPR). We have shown that modulation of these pathways impacts on the generation of CD4-responses and this work is now in a pre-clinical phase. The importance of circulating DC including CD1c+ myeloid and SlanDC (collaboration with Dr. Marc Schmitz, Dresden) in advanced cancer patients is a major focus.

Other research (collaboration with Prof Uwe Aickelin) concerns computational simulation of the balance of peripheral iTreg and Th17 responses in healthy immune aging (immunosenescence). This important programme will allow us to understand the immune-status of patients with a view to optimising their immunotherapy.

Past Research

Next-generation BCG-immunotherapy

BCG-Immunotherapy of bladder cancer

Anti-TNF strategies for rheumatoid arthritis

Future Research

Developing new first-in-man immunotherapies for cancer based on ex vivo DC vaccines, incorporating specific inhibitors of intracellular signalling pathways.

School of Medicine

University of Nottingham
Medical School
Nottingham, NG7 2UH

Contacts: Please see our 'contact us' page for further details